Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

AAP financial measures and the reconciliation of non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS to adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS for the quarter and years ended December 31, 2010 and 2009 (in millions, except per share amounts): Three months ended December 31,Year ended December 31,2010200920102009GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS

$
2.6

$
.01$
4.1

$
.01$
223.6

$
.68$
93.5

$
.30Purchase accounting related amortization (a)

91.672.4309.2282.5Litigation settlements, net

112.8114.2127.1225.7Interest, primarily amortization of debt discount, net

18.011.260.042.9Financing related costs

22.4-37.4-Acquisition related costs(b)

0.2-12.7Integration & other special items (c)

18.740.868.571.6Tax effect of the above items (d)

(86.9)(135.0)(252.8)(272.5)Preferred dividend

17.3

(e) 34.8

(e) 121.6

(e) 139.0

(e) Adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS

$
96.7

$
.45$
42.5

$
.33$
707.3

$
.61$
582.7

$
.30(a)  This amount is included in cost of sales.

(b)  This amount is included in SG&A.  

(c)  Integration and other special items include charges related to the integration of acquired businesses as well as certain restructuring items, losses on sales of certain non-operating assets, severance and employee benefit related charges.

-  For the three months ended December 31, 2010, $4.0 million of these expenses, ne
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , , , , , , Other important parameters for optimizing electroporation. , , ... Field strength , , ... field pulses , Adjustment , ... of DNA/RNA , Influence , ...
... , , Dr. Frank Stahl , ... (Society for Biotechnological Research) , , , , , ... DNA microarrays are a key technology in modern molecular biotechnology. , ... of complex genetic changes, thereby enabling a deeper insight ...
... , , Note: Genomic DNA is fragile. High molecular weight DNA ... tips or equipment when , pipetting genomic DNA. Do not vortex ... Place a 1 cm tail sample into a 1.5 ml microcentrifuge tube; ... To minimize possible cross-contamination, , do not ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Optimizing electroporation parameters 6An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 2An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 3An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 4An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 5An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 6Mouse Tail Genomic DNA Isolation Protocol(1) 2
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... , WHAT: EPA,s top scientist and the ,father of ... our nation,s first preeminent scientist and inventor Benjamin Franklin ... Philadelphia Science Festival. Park visitors and local college ... innovation and invention, and how the current generation can ...
... high-quality assisted reproduction treatment as defined by the European ... ESHRE position paper on Good clinical treatment in Assisted ... patients should be treated the same and with the ... not always the case. The Guide is based ...
... professor in the Virginia Tech Carilion Research Institute and ... and Sciences, has been invited to speak at a ... 11-12 on the security implications of advances in neuroscience. ... four-part policy study on neuroscience and society called Brain ...
Cached Biology News:ESHRE sets standards for cross-border reproductive care 2ESHRE sets standards for cross-border reproductive care 3
...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
... The MBS Satellite Thermal ... and flexible solution for medium ... The MBS combines the latest ... friendly software and PC control, ...
... The AccuSpot automates LC microfractionaction, spotting ... With the AccuSpot system, LC eluent can ... plates, in trace amounts (eg.50nl). Matrix solutions ... automatic preparation of target plated for MALDI-TOF-MS ...
Biology Products: